Lotus Eye Hospital and Institute Management

Management criteria checks 4/4

Lotus Eye Hospital and Institute's CEO is Kuttapalayam Ramalingam, appointed in Aug 2020, has a tenure of 3.67 years. directly owns 1.43% of the company’s shares, worth ₹18.14M. The average tenure of the management team and the board of directors is 3.6 years and 4.3 years respectively.

Key information

Kuttapalayam Ramalingam

Chief executive officer

₹1.2m

Total compensation

CEO salary percentage	n/a
CEO tenure	3.7yrs
CEO ownership	1.4%
Management average tenure	3.6yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO

Kuttapalayam Ramalingam (74 yo)

3.7yrs

Tenure

₹1,200,000

Compensation

Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kuttapalayam Ramalingam	CEO & Executive Director	3.7yrs	₹1.20m	1.43% ₹ 18.1m
Ramanujam Reghunathan	Chief Financial Officer	1.9yrs	₹1.55m	no data
M. Menon	Company Secretary & Compliance Officer	2.2yrs	₹981.00k	no data
Sangeetha Sundaramoorthy	MD & Director	3.6yrs	₹1.20m	18.84% ₹ 238.2m
Rajkumar Sundaramoorthy	Vice President of Administration	5.9yrs	no data	1.36% ₹ 17.2m

3.6yrs

Average Tenure

66yo

Average Age

Experienced Management: 532998's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kuttapalayam Ramalingam	CEO & Executive Director	3.2yrs	₹1.20m	1.43% ₹ 18.1m
Sangeetha Sundaramoorthy	MD & Director	4.4yrs	₹1.20m	18.84% ₹ 238.2m
Rajkumar Sundaramoorthy	Vice President of Administration	4.3yrs	no data	1.36% ₹ 17.2m
Devarayapuram Kaarthikeyan	Non-Executive Independent Director	16.5yrs	₹200.00k	no data
Kavetha Sundaramoorthy	Chairman of the Board	7.9yrs	₹200.00k	18.78% ₹ 237.4m
Yogesh Shah	Non-Executive Independent Director	16.5yrs	₹200.00k	no data
Marappa Alagiriswamy	Non-Executive Independent Director	11.9yrs	₹200.00k	no data
Sengodagounder Natesan	Independent Director	3.3yrs	₹200.00k	no data
Gopalakrishnan Veeramani	Independent Non-Executive Director	1.3yrs	₹50.00k	no data
Perumalsamy Mahendran	Independent Non-Executive Director	1.2yrs	no data	no data

4.3yrs

Average Tenure

74.5yo

Average Age

Experienced Board: 532998's board of directors are considered experienced (4.3 years average tenure).

Lotus Eye Hospital and Institute Management

Management criteria checks 4/4

Key information

Recent management updates

Vice President of Administration recently sold ₹173m worth of stock

Vice President of Administration recently sold ₹18m worth of stock

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 25, 2023

Vice President of Administration recently bought ₹1.7m worth of stock

Vice President of Administration recently bought ₹1.9m worth of stock

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 22, 2022

Recent updates

Vice President of Administration recently sold ₹173m worth of stock

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 24%

Lotus Eye Hospital and Institute Limited to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2024 earnings released: EPS: ₹0.32 (vs ₹0.56 in 3Q 2023)

Vice President of Administration recently sold ₹18m worth of stock

Second quarter 2024 earnings released: EPS: ₹0.41 (vs ₹0.43 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Upcoming dividend of ₹0.50 per share at 0.6% yield

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 25, 2023

First quarter 2024 earnings released: EPS: ₹0.67 (vs ₹0.66 in 1Q 2023)

Lotus Eye Hospital and Institute Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 22%

Vice President of Administration recently bought ₹1.7m worth of stock

Vice President of Administration recently bought ₹1.9m worth of stock

Full year 2023 earnings released: EPS: ₹1.96 (vs ₹1.44 in FY 2022)

Lotus Eye Hospital and Institute Limited Recommends Final Dividend for the Financial Year 2022-23

Investor sentiment improves as stock rises 29%

Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.67 in 3Q 2022)

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.60 in 2Q 2022)

Investor sentiment improved over the past week

Lotus Eye Hospital and Institute Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: EPS: ₹0.66 (vs ₹0.09 loss in 1Q 2022)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹1.44 (vs ₹0.75 in FY 2021)

Lotus Eye Hospital and Institute Limited Announces Appointment of Ramanujam Reghunathan as Chief Financial Officer

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Lotus Eye Hospital and Institute Limited Appoints M Achuth Menon as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹0.50 per share

First quarter 2022 earnings released: ₹0.09 loss per share (vs ₹0.32 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS ₹0.75 (vs ₹0.51 in FY 2020)

CEO & Additional Executive Director recently bought ₹2.0m worth of stock

MD & Whole Time Director recently bought ₹240k worth of stock

New 90-day high: ₹39.55

Third quarter 2021 earnings released: EPS ₹0.51 (vs ₹0.08 in 3Q 2020)

Lotus Eye Hospital and Institute Limited Announces Executive Appointments

Lotus Eye Hospital and Institute Limited Announces Demise of Founder Dr. S.K. Sundaramoorthy

New 90-day high: ₹38.00

New 90-day high: ₹34.40

Chief Executive Officer recently bought ₹2.0m worth of stock

New 90-day high: ₹33.20

MD & Whole Time Director recently bought ₹198k worth of stock

Second quarter 2021 earnings released: EPS ₹0.04

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Nov 28, 2020

Lotus Eye Hospital and Institute Limited to Report First Half, 2021 Results on Nov 11, 2020

Chief Executive Officer recently bought ₹229k worth of stock

First quarter earnings released

New 90-day high - ₹35.00

Lotus Eye Hospital and Institute Limited to Report Q1, 2021 Results on Aug 31, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age